Home Other Building Blocks N-Desmethylclozapine

N-Desmethylclozapine

CAS No.:
6104-71-8
Catalog Number:
AG00EB3S
Molecular Formula:
C17H17ClN4
Molecular Weight:
312.7967
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
≥98%
1 week
United States
$160
- +
10mg
≥98%
1 week
United States
$232
- +
25mg
99%
1 week
United States
$557
- +
50mg
≥98%
1 week
United States
$725
- +
100mg
≥98%
1 week
United States
$1290
- +
Product Description
Catalog Number:
AG00EB3S
Chemical Name:
N-Desmethylclozapine
CAS Number:
6104-71-8
Molecular Formula:
C17H17ClN4
Molecular Weight:
312.7967
MDL Number:
MFCD00210189
IUPAC Name:
3-chloro-6-piperazin-1-yl-11H-benzo[b][1,4]benzodiazepine
InChI:
InChI=1S/C17H17ClN4/c18-12-5-6-15-16(11-12)21-17(22-9-7-19-8-10-22)13-3-1-2-4-14(13)20-15/h1-6,11,19-20H,7-10H2
InChI Key:
JNNOSTQEZICQQP-UHFFFAOYSA-N
SMILES:
Clc1ccc2c(c1)N=C(N1CCNCC1)c1c(N2)cccc1
UNII:
1I9001LWY8
Properties
Complexity:
421  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
312.114g/mol
Formal Charge:
0
Heavy Atom Count:
22  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
312.801g/mol
Monoisotopic Mass:
312.114g/mol
Rotatable Bond Count:
1  
Topological Polar Surface Area:
39.7A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.6  
Literature
Title Journal
The Value of Desmethylclozapine and Serum CRP in Clozapine Toxicity: A Case Report. Case reports in psychiatry 20120101
Effect of food on the pharmacokinetics of clozapine orally disintegrating tablet 12.5 mg: a randomized, open-label, crossover study in healthy male subjects. Clinical drug investigation 20090101
Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes. Drug metabolism and disposition: the biological fate of chemicals 20081201
Massively parallel screening of the receptorome. Combinatorial chemistry & high throughput screening 20080701
Bioequivalence of clozapine orally disintegrating 100-mg tablets compared with clozapine solid oral 100-mg tablets after multiple doses in patients with schizophrenia. Clinical drug investigation 20080101
Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation. Molecular pharmacology 20061201
High throughput therapeutic drug monitoring of clozapine and metabolites in serum by on-line coupling of solid phase extraction with liquid chromatography-mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060413
Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC neuroscience 20060101
Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms. Schizophrenia research 20051215
Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatric disease and treatment 20050601
An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. International clinical psychopharmacology 20050501
Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. The Journal of pharmacology and experimental therapeutics 20050301
Field-amplified sample stacking in capillary electrophoresis for the determination of clozapine, clozapine N-oxide, and desmethylclozapine in schizophrenics' plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040925
Effects of clozapine and its metabolites on the 5-HT2 receptor system in cortical and hippocampal cells in vitro. Progress in neuro-psychopharmacology & biological psychiatry 20040301
Differing response to antipsychotic therapy in schizophrenia: pharmacogenomic aspects. Dialogues in clinical neuroscience 20040301
N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proceedings of the National Academy of Sciences of the United States of America 20031111
Pharmacokinetics of clozapine and its metabolites in hippocampal HT22 cells. European journal of pharmacology 20030829
Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacology, biochemistry, and behavior 20030501
Central effects of clozapine in regulating micturition in anesthetized rats. BMC pharmacology 20020101
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. Journal of child and adolescent psychopharmacology 20020101
Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain research 20011227
Tertiary N-glucuronides of clozapine and its metabolite desmethylclozapine in patient urine. Drug metabolism and disposition: the biological fate of chemicals 20011001
Isolation and identification of clozapine metabolites in patient urine. Drug metabolism and disposition: the biological fate of chemicals 20010601
Rapid capillary electrophoretic method for the determination of clozapine and desmethylclozapine in human plasma. Journal of chromatography. A 20010504
Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo. Drug metabolism and drug interactions 20010101
Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. European journal of clinical pharmacology 20001101
Metabolites of the antipsychotic agent clozapine inhibit the replication of human immunodeficiency virus type 1. Schizophrenia research 19970503
Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 19950201
Properties